Cited by 63Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project

Open access
Timmers, Tessa, Ossenkoppele, Rik, Verfaillie, Sander C.J., van der Weijden, Chris W.J., Slot, Rosalinde E.R., Wesselman, Linda M.P., Windhorst, Albert D., Wolters, Emma E. +6 more·2019·Neurobiology of Aging

Abstract

We examined the relationships between amyloid-β PET and concurrent and longitudinal cognitive performance in 107 cognitively normal individuals with subjective cognitive decline (age: 64 ± 8 years, 44% female, Mini-Mental State Examination score 29 ± 1). All underwent 90-minute dynamic [ 18 F]florbetapir PET scanning and longitudinal neuropsychological tests with a mean follow-up of 3.4 ± 3.0 years. Receptor parametric mapping was used to calculate [ 18 F]florbetapir binding potential (BP ND ), and we performed linear mixed models to assess the relationships between global [ 18 F]florbetapir BP ND and neuropsychological performance. Higher [ 18 F]florbetapir BP ND was related to lower concurrent Mini-Mental State Examination (β ± SE: −1.69 ± 0.63 p < 0.01) and to steeper rate of decline on tasks capturing memory (Rey Auditory Verbal Learning Task immediate [β ± SE −1.81 ± 0.81, p < 0.05] and delayed recall [β ± SE −1.19 ± 0.34, p < 0.01]), attention/executive functions (Stroop II [color] [β ± SE −0.02 ± 0.01, p < 0.05], Stroop III [word-color] [β ± SE −0.03 ± 0.02, p < 0.05]), and language (category fluency [β ± SE −0.04 ± 0.01, p < 0.01]). These findings suggest that higher amyloid-β load in cognitively normal individuals with subjective cognitive decline from a memory clinic is associated with lower concurrent global cognition and with faster rate of decline in a variety of cognitive domains.

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2019.02.020

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Higher amyloid aggregation at baseline indicated a faster rate of decline in various cognition domains and a more rapid increase in SCD severity over time in individuals with SCD.

    “Recently, several studies have consistently suggested that higher amyloid aggregation at baseline indicated a faster rate of decline in various cognition domains [37, 38] and a more rapid increase in SCD severity over time [39] in individuals with SCD.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Timmers, T., Ossenkoppele, R., Verfaillie, S. C. J., van der Weijden, C. W. J., Slot, R. E. R., Wesselman, L. M. P., Windhorst, A. D., Wolters, E. E., Yaqub, M., Prins, N. D., Lammertsma, A. A., Scheltens, P., van der Flier, W. M., & van Berckel, B. N. M.
Affiliations
  • Amsterdam University Medical Centers (NL)
  • Lund University (SE)
Corresponding author
Timmers, Tessa
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2019-07
Volume
79
Pages
50-58
ISSN
0197-4580 (ISSN-L)
OpenAlex
W2920874722
Cited by
63
References
61
Citations by year
2026: 7 · 2025: 7 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 14 · 2020: 8 · 2019: 3
FWCI
6.99
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Aging (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
Funders
  • Alzheimer Nederland
  • Amsterdam Neuroscience
  • GIESKES-STRIJBIS FONDS
  • Avid Radiopharmaceuticals
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
amyloid PET, 18F-florbetapir, binding potential, subjective cognitive decline, cognitively normal individuals, cognitive decline, memory decline, executive function, attention, language, Mini-Mental State Examination
MeSH terms
Aged, Cognition, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Amyloid beta-Peptides, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review